Cardioprotective effect of early dexrazoxane use in anthracycline treated pediatric patients

Anthracyclines play a major role in chemotherapeutic regimens for a variety of pediatric cancers, but produce undesirable dose-related cardiotoxicity. Dexrazoxane reduces early myocardial injury during anthracycline treatment, but data remain insufficient to fully understand its cardioprotective eff...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2012-10, Vol.24 (5), p.292-296
Main Authors: Kang, Minkyoung, Kim, Kyung Im, Song, Young-cheon, Shin, Wan Gyoon, Oh, Jung Mi
Format: Article
Language:English
Subjects:
Adolescent
Age Factors
Anthracycline
Anthracyclines - adverse effects
Anthracyclines - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Cardiotoxicity
Cardiovascular Agents - administration & dosage
Cardiovascular Agents - therapeutic use
Cardiovascular Diseases - chemically induced
Cardiovascular Diseases - prevention & control
Child
Child, Preschool
Dexrazoxane
Female
Heart Function Tests
Hospitals, Teaching
Humans
Infant
Male
Medical sciences
Neoplasms - drug therapy
Pediatric
Pharmacology. Drug treatments
Prevention
Razoxane - administration & dosage
Razoxane - therapeutic use
Republic of Korea
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anthracyclines play a major role in chemotherapeutic regimens for a variety of pediatric cancers, but produce undesirable dose-related cardiotoxicity. Dexrazoxane reduces early myocardial injury during anthracycline treatment, but data remain insufficient to fully understand its cardioprotective effectiveness in treating pediatric cancers and additional research is necessary to find efficient methods of dexrazoxane administration. Therefore, we retrospectively evaluated the cardioprotective effect of dexrazoxane against anthracyclines in 258 pediatric cancer patients who had received any anthracyclines from January 1997 to May 2005 at a tertiary teaching hospital in Korea. The results of this study suggest that the early use of dexrazoxane protects against the development of cardiotoxicity during anthracycline treatment in pediatric cancer patients. Further studies involving larger pediatric cancer patients are needed to evaluate the cardioprotective effect of dexrazoxane at higher cumulative doses of anthracyclines and on late-onset cardiotoxicity in long-term survivors.
ISSN:1120-009X
1973-9478
DOI:10.1179/1973947812Y.0000000038